FrancophonIA/ELRC3.0 huggingface dataset:
English: The patient must take the tablet with a full glass of water (but not mineral water), at least 30 minutes before any food, drink or other medicines (including antacids, calcium supplements and vitamins).
Estonian: Patsient peab tableti võtma terve klaasi veega (mitte mineraalveega) vähemalt 30 minutit enne söögi, joogi või muu ravimi (sh antatsiidide, kaltsiumipreparaatide ja vitamiinide) võtmist.
English: The CHMP decided that Fosavance's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Fosavance kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Fosavance, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Fosavancega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: for the full list of restrictions, see the package leaflet.
Estonian: Piirangute täielik loetelu on pakendi infolehel.
English: Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight, it is included in Fosavance.
Estonian: Et osteoporoosiga patsiendid ei tarvitse saada päikesevalgusega piisavalt D3-vitamiini, sisaldab seda Fosavance.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Fosavance, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Fosavance omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Fosavance alendronic acid and colecalciferol
Estonian: Fosavance alendroonhape ja kolekaltsiferool
English: This is a summary of the European public assessment report (EPAR) for Fosavance.
Estonian: See on ravimi Fosavance Euroopa avaliku hindamisaruande kokkuvõte.
English: Fosavance 70 mg/5,600 IU is for use in patients who are not taking vitamin D supplements.
Estonian: 70 mg/5600 IU Fosavancet kasutatakse patsientidel, kes ei võta täiendavalt D-vitamiini.
English: To avoid irritation of the oesophagus (the tube that leads from the mouth to the stomach), the patient should not lie down until after their first food of the day, which should be at least 30 minutes after taking the tablet.
Estonian: Söögitoru ärritusnähtude vältimiseks tohib patsient pikali heita alles pärast päeva esimest söögikorda, mis peaks olema vähemalt 30 minutit pärast tableti võtmist.
English: Fosavance must not be used in patients who have abnormalities of the oesophagus, who have hypocalcaemia (low blood calcium levels), or who cannot stand or sit upright for at least 30 minutes.
Estonian: Fosavancet ei tohi kasutada patsientidel, kellel on söögitoru häired, hüpokaltseemia (kaltsiumivaegus) või kes ei saa vähemalt 30 minutit püsti seista või sirgelt istuda.
English: The information presented by the company from earlier studies and the published literature showed that the dose of alendronic acid included in Fosavance was the same as the dose needed to prevent bone loss.
Estonian: Ettevõtte esitatud teave, mis põhines varasematel uuringutel ja avaldatud teaduskirjandusel, näitas, et Fosavances sisalduv alendroonhappe kogus on samane luukoe hävimise ennetamiseks vajaliku kogusega.
English: Because alendronic acid and vitamin D3 are already used separately in authorised medicines in the European Union (EU), the company presented data obtained in earlier studies and from the published literature from women who had been through the menopause and who were taking alendronic acid and vitamin D as separate tablets.
Estonian: Et alendroonhape ja D3-vitamiin on kumbki kasutusel ravimites, millel juba on Euroopa Liidus müügiluba, esitas ettevõte varasematest uuringutest saadud ja kirjanduses avaldatud andmed menopausijärgses eas naiste kohta, kes võtsid alendroonhapet ja D-vitamiini eraldi tablettidena.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fosavance.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Other information about Fosavance:
Estonian: Muu teave Fosavance kohta
English: For the full list of all side effects reported with Fosavance, see the package leaflet.
Estonian: Fosavance kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is Fosavance?
Estonian: Mis on Fosavance?
English: Why has Fosavance been approved?
Estonian: Miks Fosavance heaks kiideti?
English: The most common side effects with Fosavance (seen between 1 and 10 patients in 100) are headache, abdominal pain (stomach ache), dyspepsia (heartburn), constipation, diarrhoea, flatulence (gas),
Estonian: Fosavance kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, kõhuvalu, düspepsia (kõrvetised), kõhukinnisus, kõhulahtisus, kõhupuhitus, söögitoru haavandid, düsfaagia (neelamisraskus), kõhu paisumine, maohappe tagasivool ja luu-lihaskonna valu (luude, liigeste ja lihaste valu).
English: Fosavance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels.
Estonian: Fosavancet (2800 IU või 5600 IU kolekaltsiferooli) kasutatakse osteoporoosi (luu-urbnemuse) raviks menopausijärgses eas naistel, kellel on D-vitamiini vaeguse risk.
English: This study was extended in 652 patients for a further 24 weeks to compare the effects of continuing with Fosavance 70 mg/2,800 IU on its own or adding another 2,800 IU vitamin D3 (equivalent to using Fosavance 70 mg/5,600 IU).
Estonian: Uuringut pikendati 652 patsiendil 24 nädala võrra, et võrrelda ravi jätkamist kas üksnes 70 mg/2800 IU Fosavancega või koos lisatud 2800 IU D3-vitamiiniga (võrdväärne 70 mg/5600 IU Fosavance kasutamisega).
English: What is the risk associated with Fosavance?
Estonian: Mis riskid Fosavancega kaasnevad?
English: Patients received either Fosavance 70 mg/2,800 IU or alendronic acid only once a week.
Estonian: Patsiendid said üks kord nädalas kas 70 mg/2800 IU Fosavancet või alendroonhapet.
English: Fosavance is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Estonian: Fosavance on ravim, mis sisaldab kaht toimeainet: alendroonhapet ja kolekaltsiferooli (D3-vitamiin).
English: To support the combination of alendronic acid and vitamin D3 in the same tablet, the company also carried out a study in 717 patients with osteoporosis, including 682 women who had been through the menopause, to show Fosavance's ability to increase vitamin D levels.
Estonian: Alendroonhappe ja D3-vitamiini ühes tabletis kasutamise ja Fosavance mõjul D-vitamiini sisalduse suurenemise toetuseks viis ettevõte lisaks läbi uuringu, milles osales 717 osteoporoosiga patsienti, sealhulgas 682 menopausijärgses eas naist.
English: In the extension study, similar numbers of patients taking Fosavance 70 mg/2,800 IU and Fosavance 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Fosavance 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
Estonian: Jätku-uuringus oli D-vitamiini vaegusega (alla 6%) patsientide arv samalaadne nii 70 mg/2800 IU kui ka 70 mg/5600 IU Fosavancet võtnute seas, kuid 70 mg/5600 IU Fosavancet manustanud patsientide D-vitamiini sisaldus suurenes 24 uuringunädala jooksul enam.
English: Fosavance contains two active substances: alendronic acid and colecalciferol (vitamin D3).
Estonian: Fosavance sisaldab kaht toimeainet: alendroonhapet ja kolekaltsiferooli (D3-vitamiin).
English: Fosavance reduces the risk of fractures (broken bones) in the spine and the hip.
Estonian: Fosavance vähendab lülisamba ja puusamurdude riski.
English: What is Fosavance used for?
Estonian: Milleks Fosavancet kasutatakse?
English: How does Fosavance work?
Estonian: Kuidas Fosavance toimib?
English: After 15 weeks, fewer patients had low vitamin D levels when they took Fosavance 70 mg/2,800 IU (11%) than when they took alendronic acid only (32%).
Estonian: Fosavancet annuses 70 mg/2800 IU manustanud patsientide seas oli 15. nädala järel D-vitamiini vaegusega patsiente vähem (11%) kui ainult alendroonhapet manustanud patsientide seas (32%).
English: What benefit has Fosavance shown during the studies?
Estonian: Milles seisneb uuringute põhjal Fosavance kasulikkus?
English: How is Fosavance used?
Estonian: Kuidas Fosavancet kasutatakse?
English: How has Fosavance been studied?
Estonian: Kuidas Fosavancet uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Fosavance on retseptiravim.
English: the dose should be reduced gradually, over at least a week.
Estonian: peab toimuma järk-järgult, vähemalt ühe nädala jooksul.
English: is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
Estonian: turustatakse kapslitena (25, 50, 75, 100, 150, 200, 225 ja 300 mg) ja see on retseptiravim.
English: is a medicine used to treat adults with the following conditions:
Estonian: on ravim, mida kasutatakse järgmiste haigusseisundite raviks täiskasvanutel:
English: This reduces the activity of nerve cells in the brain and spinal cord that are involved in pain, epilepsy and anxiety.
Estonian: See vähendab selliste peaaju ja seljaaju närvirakkude talitlust, mis tekitavad valu, epilepsiat ja ärevust.
English: contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
Estonian: sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Lyrica, millel juba on Euroopa Liidus müügiluba.
English: • neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with herpes zoster (shingles) or nerve disorders caused by diabetes,
Estonian: • neuropaatiline valu (närvikahjustusest põhjustatud valu), sh perifeerne neuropaatiline valu, nt vöötohatisega (herpes zoster) või diabeedist põhjustatud närvisüsteemi häiretega patsientidel, ja tsentraalne neuropaatiline valu, nt valu, mis esineb patsientidel pärast seljaaju vigastust;
English: contains the active substance pregabalin.
Estonian: sisaldab toimeainena pregabaliini.
English: The active substance in Pregabalin Zentiva k.s., pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Estonian: toimeaine pregabaliin sarnaneb struktuurilt organismi loodusliku neurotransmitteri gamma-aminobutüürhappega (GABA), kuid on täiesti teistsuguse bioloogilise toimega.
English: After three to seven days, the dose can be increased to 300 mg per day.
Estonian: Kolme kuni seitsme päeva möödudes tohib ravimi ööpäevast annust suurendada 300 mg-ni. Annust tohib kahekordistada, kuni on saavutatud efektiivseim annus.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Zentiva k.s.
Estonian: Võrdlusravimiga Lyrica on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Pregabalin Zentiva k.s.
English: has been shown to have comparable quality and to be bioequivalent to Lyrica.
Estonian: võrreldav kvaliteet ja bioekvivalentsus ravimiga Lyrica.
English: Doctors may choose lower doses in patients with kidney problems.
Estonian: Neerutalitluse häiretega patsientidele võib arst määrata väiksemad annused.
English: As for every medicine, the company provided studies on the quality of Pregabalin Zentiva k.s.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud ravimi Pregabalin Zentiva k.s.
English: For practical information about using Pregabalin Zentiva k.s., patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva k.s.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Pregabalin Zentiva k.s.
English: For more information about treatment with Pregabalin Zentiva k.s., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
Estonian: • epilepsia, mille korral seda ravimit kasutatakse lisaks senisele ravile patsientidel, kelle partsiaalsed episoodid (aju teatud osas algavad epilepsiaepisoodid) ei ole reageerinud senisele ravile;
English: What measures are being taken to ensure the safe and effective use of Pregabalin Zentiva k.s.
Estonian: Mis meetmed võetakse, et tagada ravimi Pregabalin Zentiva k.s.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Zentiva k.s.
Estonian: ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva k.s.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Pregabalin Zentiva k.s.
English: Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Lyrica korral, ületab ravimi Pregabalin Zentiva k.s.
English: When stopping treatment with Pregabalin Zentiva k.s.
Estonian: Ka ravi katkestamine ravimiga Pregabalin Zentiva k.s.
English: The Committee recommended that Pregabalin Zentiva k.s.
Estonian: Komitee soovitas ravimi Pregabalin Zentiva k.s.
English: This means that Pregabalin Zentiva k.s.
Estonian: See tähendab, et Pregabalin Zentiva k.s.
English: Because Pregabalin Zentiva k.s.
Estonian: Et Pregabalin Zentiva k.s.
English: What is Pregabalin Zentiva k.s.
Estonian: Mis on Pregabalin Zentiva k.s.
English: Why is Pregabalin Zentiva k.s.
Estonian: Miks Pregabalin Zentiva k.s.
English: How has Pregabalin Zentiva k.s.
Estonian: Kuidas Pregabalin Zentiva k.s.
English: The MAH commits to respond to a number of unresolved quality related issues by presenting relevant and adequate documents and data as outlined in the Letter of Undertaking dated 9 December 2009.
Estonian: Müügiloa hoidja kohustub vastama mitmele lahendamata kvaliteediküsimusele, esitades asjakohased ja adekvaatsed dokumendid ning andmed, nagu märgitud 9. detsembri 2009 kohustuskirjas.
English: To reduce administrative work, all response documents should be submitted as a single data package one year after the issue of the EC decision.
Estonian: Haldustegevuse vähendamiseks tuleb kõik vastuse dokumendid esitada ühe andmepakmena 1 aasta pärast Euroopa Komisjoni otsuse avaldamist.
English: The full EPAR for Clynav can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Clynavi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Protection lasts approximately three months after vaccination at average water temperature of 12 ±2 °C.
Estonian: Immuunsus püsib ligikaudu 3 kuud pärast vaktsineerimist keskmisel veetemperatuuril 12 ± 2 °C.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clynav's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Clynavi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: The most common side effects with Clynav (which may affect more than 1 in 10 fish) are short lived changes in swimming behaviour for up to two days, altered pigmentation (colouration) for up to seven days and lack of appetite for up to nine days.
Estonian: Clynavi kõige sagedamad kõrvaltoimed (võivad esineda rohkem kui 1 kalal 10st) on lühiajalised, kuni 2-päevased muutused ujumiskäitumises, kuni 7-päevased pigmentatsiooni (värvuse) muutused ja kuni 9-päevane isutus.
English: The time for protection to develop following vaccination depends on the water temperature: protection starts within 399 degree days, calculated as mean water temperature in °C multiplied by number of days, for example 40 days at a water temperature of 10 °C.
Estonian: Vaktsineerimisjärgse kaitse tekkimise aeg sõltub veetemperatuurist: immuunsus tekib 399 kraadööpäeva jooksul, mis arvutatakse kui keskmine veetemperatuur °C korrutatuna päevade arvuga; näiteks 40 päeva veetemperatuuril 10 °C.
English: Clynav is a DNA vaccine.
Estonian: Clynav on DNA-vaktsiin.
English: This is a summary of the European public assessment report (EPAR) for Clynav.
Estonian: See on ravimi Clynav Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Clynav:
Estonian: Muu teave Clynavi kohta
English: Why is Clynav approved?
Estonian: Miks Clynav heaks kiideti?
English: Pancreas disease in Atlantic salmon can lead to impaired daily weight gain, lesions of the heart, pancreas and skeletal muscle as well as death.
Estonian: Pankreasetõbi võib Atlandi lõhedel vähendada igapäevast kaaluiivet, põhjustada kahjustusi südames, kõhunäärmes ja skeletilihases ning ka surma.
English: In the future, if the fish are exposed to the virus, the immune system will be able to respond more quickly.
Estonian: Kui kalad puutuvad hiljem viirusega uuesti kokku, tekivad antikehad kiiremini.
English: What is Clynav and what is it used for?
Estonian: Mis on Clynav ja milleks seda kasutatakse?
English: In case of accidental needle stick or self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Juhusliku nõelatorke või enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata talle pakendi infolehte või etiketti.
English: It is not intended to provide practical advice on how to use Clynav.
Estonian: Hindamisaruandes ei anta Clynavi kasutamise praktilisi nõuandeid.
English: What are the risks associated with Clynav?
Estonian: Mis riskid Clynaviga kaasnevad?
English: The vaccine is given to anaesthetised fish as a single injection into epaxial muscle (muscle of the upper half of the fish) in the area to the front and side of the dorsal fin.
Estonian: Vaktsiin manustatakse narkoosis kaladele ühekordse süstena epaksiaalsesse lihasesse (kala ülemisel poolel olevasse lihasesse) seljauimest ettepoole ja külgsuunas.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences)
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: Following artificial infection by co-habitation with infected salmon 29 days and 3 months after vaccination, fish vaccinated with Clynav had improved weight gain, reduced heart, pancreas and skeletal muscle lesions and reduced risk of death compared to fish injected with the dummy saline injection.
Estonian: Kalad nakatati kunstlikult 29 päeva ja 3 kuud pärast vaktsineerimist, hoides neid ühes elukeskkonnas nakatunud kaladega, misjärel oli Clynaviga vaktsineeritud kaladel parem kaaluiive, vähem südame, kõhunäärme ja skeletilihase kahjustuskoldeid ja väiksem surmarisk võrreldes füsioloogilise lahuse platseebosüsti saanud kaladega.
English: Clynav is a veterinary vaccine used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3).
Estonian: Clynav on veterinaarvaktsiin, mida kasutatakse Atlandi lõhede kaitseks lõhelaste alfaviiruse 3. alatüübi (SAV3) poolt põhjustatud pankreasetõve eest.
English: Direct contact should be avoided and protective equipment (for example protective gloves) should be worn when handling the medicine.
Estonian: Vältima peab otsest kokkupuudet ravimiga ja ravimi käsitsemise ajal peab kasutama kaitsevahendeid (nt kindaid).
English: Six laboratory studies were conducted in fresh water and sea water to show how effective the vaccine was in protecting salmon from disease caused by SPDV.
Estonian: Mage- ja merevees tehti kuus laboriuuringut, et tõestada vaktsiini efektiivsus lõhede kaitsmisel lõhe pankreasetõve viiruse põhjustatud haiguse eest.
English: The withdrawal period for fish from Atlantic salmon treated with Clynav is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Vaktsiiniga Clynav vaktsineeritud Atlandi lõhede keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad Clynavi kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: A main laboratory model study looked at the signs of pancreas disease in fish given Clynav compared with a dummy saline injection.
Estonian: Põhilises mudel-laboriuuringus vaadeldi pankreasetõve tunnuseid Clynavi saanud kaladel võrreldes kaladega, kes olid saanud platseebosüsti füsioloogilise lahusega.
English: For the full list of all side effects reported with Clynav, see the package leaflet.
Estonian: Clynavi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The immune system recognises these virus proteins as ‘foreign' and makes defences against them.
Estonian: Immuunsüsteem peab neid viiruse valke võõraks ja tekitab nende vastu antikehi.
English: How does Clynav work?
Estonian: Kuidas Clynav toimib?
English: Clynav salmon pancreas disease vaccine (recombinant DNA plasmid)
Estonian: Clynav lõhe pankreasetõve vaktsiin (rekombinant-DNA-plasmiid)
English: The European Commission granted a marketing authorisation valid throughout the EU for Clynav on
Estonian: Euroopa Komisjon andis Clynavi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27.06.2017.
English: How is Clynav used?
Estonian: Kuidas Clynavi kasutatakse?
English: What benefits of Clynav have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Clynavi kasulikkus?
English: Clynav contains as active substance a DNA plasmid (a small piece of DNA) containing the genetic code for making salmon pancreas disease virus proteins.
Estonian: Clynav sisaldab toimeainena DNA-plasmiidi (väikest DNA-molekuli), mis kodeerib lõhe pankreasetõve viiruse valke.
English: Needle injuries at the site of injection are common following vaccination and can persist for at least 90 days.
Estonian: Pärast vaktsineerimist tekib süstekohta sageli nõelavigastus, mis võib püsida vähemalt 90 päeva.
English: Clynav is available as a solution for injection and can only be obtained with a prescription.
Estonian: Clynavi turustatakse süstelahusena ja see on retseptivaktsiin.
English: Clynav contains a DNA plasmid which, once injected into fish, will lead to the production of salmon pancreas disease virus (SPDV) proteins.
Estonian: Clynav sisaldab DNA-plasmiidi, mis kalale süstituna
English: Wash your hands thoroughly.
Estonian: Peske hoolikalt käed.
English: Your doctor will tell you how much LITAK you need and how often and when you have to inject yourself.
Estonian: Arst ütleb teile, kui palju LITAKit te vajate ja kui tihti ja millal te peate ennast süstima.